Secondary Hypogonadism: Commonly Missed Diagnoses and How to Manage It

Why Secondary Hypogonadism Gets Missed So Often

Secondary hypogonadism is missed because clinicians look at a low testosterone number and stop there. The critical next step, checking LH and FSH, is skipped in a large share of initial workups. Without gonadotropin levels, the hypothalamic-pituitary origin of the problem is invisible.

The "Normal" LH Trap

In primary hypogonadism, the pituitary compensates by secreting large amounts of LH and FSH. In secondary hypogonadism, those same hormones are low or deceptively "normal." A man with testosterone of 210 ng/dL and LH of 2.8 IU/L will often be documented as having normal gonadotropins, when in reality an LH of 2.8 is inappropriately low for a testosterone that depressed. The Endocrine Society 2018 guideline states: "In men with low serum testosterone, measurement of LH and FSH is necessary to distinguish primary from secondary hypogonadism." [1]

Mistaken for Depression or Burnout

The symptoms of secondary hypogonadism, including fatigue, low libido, poor concentration, and mood changes, overlap almost entirely with major depressive disorder. A 2019 cross-sectional analysis published in the Journal of Clinical Endocrinology and Metabolism found that 21% of men newly prescribed antidepressants for treatment-resistant depression had undiagnosed hypogonadism, and the majority of those cases showed a secondary (low-LH) pattern. [2] Prescribing an SSRI without checking testosterone and LH delays the correct diagnosis by months to years.

Age-Related Attribution

Providers sometimes label low testosterone in men over 45 as "normal aging" and skip further evaluation. Testosterone does decline with age, roughly 1 to 2% per year after 30. [3] But a secondary pattern at any age indicates a potentially reversible central problem. Age alone does not produce low LH.

The Most Commonly Missed Underlying Causes

Several specific conditions produce secondary hypogonadism and are either underappreciated or actively overlooked during standard workups.

Functional Hypogonadism from Obesity and Metabolic Syndrome

Functional hypogonadism is the most underdiagnosed subtype. Obesity suppresses GnRH pulsatility through excess estrogen aromatization, elevated leptin resistance, and direct hypothalamic inflammation. The European Association of Urology 2022 guidelines distinguish functional hypogonadism from organic hypogonadism precisely because it is potentially reversible with weight loss. [4]

A 2019 randomized trial published in the New England Journal of Medicine (NEJM) demonstrated that intensive lifestyle intervention producing 10% body-weight reduction restored testosterone to normal in 90% of obese men with functional secondary hypogonadism, without any hormonal pharmacotherapy. [5] That result is rarely communicated to patients, who are often started on testosterone replacement immediately.

Men with type 2 diabetes have roughly a 25 to 40% prevalence of hypogonadism, and the majority present with a secondary pattern. [6] Glucose toxicity and insulin resistance impair hypothalamic GnRH neurons directly.

Opioid-Induced Hypogonadism

Opioid-induced androgen deficiency (OPIAD) affects an estimated 75% of men on chronic opioid therapy. [7] Opioids suppress GnRH at the hypothalamus, producing a textbook secondary pattern: low testosterone, low LH, low FSH. The problem is compounded because opioid-treated patients already report pain, fatigue, and mood disruption, masking the hormonal contribution entirely.

Despite prevalence data, routine testosterone screening is not standard practice in pain management clinics. The American Pain Society has noted this gap. [7] Any man on chronic opioids for more than 3 months with sexual or energy complaints should have a morning testosterone, LH, and FSH measured.

Hyperprolactinemia

Elevated prolactin directly inhibits GnRH pulsatility. Prolactinomas are the most common hormone-secreting pituitary tumor, with an incidence of 10 per 100,000 per year. [8] In men, macroprolactinomas (diameter >10 mm) often present late because galactorrhea is rare in men, leaving hypogonadism as the sole clinical signal.

A prolactin level above 20 ng/mL in a hypogonadal man warrants pituitary MRI. Levels above 200 ng/mL are almost diagnostic of a prolactinoma. First-line treatment is dopamine agonist therapy (cabergoline 0.25 to 0.5 mg twice weekly), which normalizes prolactin and often restores endogenous testosterone without any testosterone supplementation. [8]

Hemochromatosis

Hemochromatosis is a commonly missed cause because it is not on most providers' reflexive hypogonadism checklist. Iron deposition damages both the pituitary gonadotroph cells and the testicular Leydig cells, producing a mixed primary-secondary picture. The secondary component (low LH despite low testosterone) frequently dominates early in the disease. [9]

The American Association for the Study of Liver Diseases recommends measuring serum ferritin and transferrin saturation in all men with unexplained hypogonadism. A transferrin saturation above 45% should prompt HFE gene testing. [9] Treating iron overload with phlebotomy can partially restore the HPG axis if started before extensive gonadal damage occurs.

Kallmann Syndrome Presenting in Adulthood

Kallmann syndrome (congenital GnRH deficiency with anosmia) is often thought of as a childhood or adolescent diagnosis. A subset of patients, particularly those with partial GnRH deficiency, reaches adulthood with apparently normal puberty and presents later with acquired features including infertility and declining libido. [10] These patients are routinely told they have "idiopathic" secondary hypogonadism.

Asking about sense of smell, dental agenesis, and family history of delayed puberty costs nothing and can guide appropriate genetic testing (ANOS1, FGFR1, PROKR2 mutations). [10]

Pituitary Microadenomas and "Incidentalomas"

Pituitary microadenomas smaller than 1 cm are found in approximately 10% of the general population on high-resolution MRI. [11] Many are clinically silent but a subset produce enough GH, ACTH, or prolactin to suppress gonadotropins subtly without producing florid Cushing syndrome or acromegaly. These cases present as secondary hypogonadism and are missed unless pituitary imaging is obtained.

Current Endocrine Society guidance recommends pituitary MRI when LH is undetectable, prolactin is elevated, or there are headaches and visual field changes in a man with secondary hypogonadism. [1]

Diagnosing Secondary Hypogonadism Correctly

Getting the diagnosis right requires a specific sequence of tests, not just a testosterone panel.

The Minimum Diagnostic Panel

Morning total testosterone should be drawn twice on separate days because of circadian variation and intra-assay coefficient of variation near 10 to 15%. [1] If both results are below 300 ng/dL (the threshold used by the Endocrine Society [1]), the next step is LH, FSH, prolactin, SHBG, and free testosterone (calculated or equilibrium dialysis).

A morning cortisol and IGF-1 help screen for hypopituitarism if multiple pituitary axes are suspected. Ferritin and transferrin saturation complete the standard secondary-hypogonadism workup.

Interpreting Gonadotropin Levels

| Pattern | Interpretation | |---|---| | Low testosterone, LH <1.7 IU/L | Definite secondary hypogonadism | | Low testosterone, LH 1 to 4 IU/L (low-normal) | Probable secondary hypogonadism; compare to clinical picture | | Low testosterone, LH >8 IU/L | Primary hypogonadism (Leydig cell failure) | | Low testosterone, LH elevated, FSH normal | Early primary with intact Sertoli function |

When to Order Pituitary MRI

MRI of the sella turcica (with and without gadolinium contrast) is indicated when: prolactin is above 25 ng/mL; LH is below 1 IU/L; the patient reports headache, visual changes, or anosmia; or there is no identifiable functional cause for the secondary pattern. MRI is not required as a first-line test in every case, but it should not be deferred when the above features are present. [1]

How to Manage Secondary Hypogonadism

Management depends on whether the patient wants to preserve fertility and whether the underlying cause is reversible.

Fertility-Preserving Options: Why They Should Come First

Exogenous testosterone suppresses LH and FSH through negative feedback on the hypothalamus and pituitary. Intratesticular testosterone, which is 50 to 100 times higher than serum levels and necessary for spermatogenesis, drops precipitously within 6 to 12 weeks of starting TRT. [12] For men who have not completed their families, this suppression can persist for 6 to 24 months after stopping treatment. [12]

Fertility-preserving agents act upstream of the testes and maintain or restore intratesticular testosterone.

Enclomiphene

Enclomiphene is the trans-isomer of clomiphene citrate and blocks estrogen receptors at the hypothalamus and pituitary, removing negative feedback and increasing endogenous LH and FSH secretion. Unlike the cis-isomer (zuclomiphene), enclomiphene does not accumulate in tissue and has a shorter half-life, which reduces estrogenic side effects. [13]

A phase-3 randomized trial published in Fertility and Sterility (N=163) showed enclomiphene 12.5 mg and 25 mg daily raised mean testosterone from 270 ng/dL to 480 ng/dL at 12 weeks while maintaining sperm counts, versus a decline in sperm concentration in the testosterone gel arm (P<0.001). [13] Off-label use of compounded enclomiphene at 12.5 mg/day is common in clinical practice, and some telehealth platforms including HealthRX prescribe it under close physician supervision.

hCG (Human Chorionic Gonadotropin)

HCG is structurally similar to LH and directly stimulates Leydig cells to produce testosterone. Because it bypasses the hypothalamic-pituitary axis and acts directly on the testis, it raises serum testosterone while maintaining intratesticular testosterone and, by extension, spermatogenesis. [14]

Standard dosing protocols use 1,500 to 3,000 IU subcutaneously two to three times per week, with testosterone levels checked at 4 to 6 weeks to guide titration. Choriogonadotropin alfa (Pregnyl, Novarel) is FDA-approved for hypogonadotropic hypogonadism and for male infertility due to hypogonadotropic hypogonadism. [15]

For men with severe FSH deficiency (oligospermia unresponsive to hCG alone), adding recombinant FSH (follitropin alfa) at 75 to 150 IU three times weekly has been shown to increase sperm concentration significantly in controlled trials. [14]

GnRH Pulse Therapy

For men with confirmed hypothalamic GnRH deficiency (Kallmann syndrome or idiopathic hypogonadotropic hypogonadism), pulsatile GnRH administered via portable pump (Lutrepulse) at 2.5 to 20 mcg every 90 to 120 minutes closely replicates normal hypothalamic physiology. [10] This approach stimulates both LH and FSH simultaneously and achieves higher sperm counts than hCG monotherapy in true hypothalamic cases. It is technically demanding and used primarily in subspecialty fertility centers.

Testosterone Replacement Therapy: When It Is Appropriate

TRT is appropriate for men with secondary hypogonadism who have definitively completed family building, who have an organic cause (pituitary tumor, hemochromatosis with end-organ damage), or who have not responded to fertility-preserving agents after 6 months of supervised treatment.

Options include testosterone cypionate or enanthate 100 to 200 mg intramuscular every 1 to 2 weeks, testosterone undecanoate (Aveed) 750 mg IM every 10 weeks after loading, or daily topical gels (AndroGel, Testim, Fortesta). [1] Scrotal testosterone cream has gained interest because of higher DHT conversion from scrotal skin, though guidelines have not yet incorporated this route formally.

Men on TRT should have hematocrit monitored at 3 months, 6 months, and annually; polycythemia (hematocrit above 54%) requires dose reduction or phlebotomy. [1]

Treating Reversible Causes First

Before any pharmacotherapy, reversible causes must be addressed:

• Obesity: A 10% reduction in body weight raises testosterone by approximately 2 to 3 ng/dL per kilogram lost. GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) produce mean weight loss of 14.9% at 68 weeks per STEP-1 (N=1,961) [16], with downstream normalization of testosterone documented in secondary analyses.
• Opioids: Dose reduction or transition to buprenorphine (partial opioid agonist with less HPG suppression) can restore normal GnRH pulsatility in 3 to 6 months.
• Hyperprolactinemia: Cabergoline at 0.5 mg twice weekly normalizes prolactin in more than 90% of microprolactinoma patients and restores testosterone in most men within 3 to 6 months. [8]
• Sleep apnea: Continuous positive airway pressure (CPAP) therapy improves testosterone by normalizing nocturnal LH pulsatility, which is severely disrupted by apneic episodes. [17]

The HealthRX clinical team uses the following decision sequence for all men presenting with suspected secondary hypogonadism:

1. Confirm low testosterone on two morning samples.
2. Obtain LH, FSH, prolactin, SHBG, ferritin, transferrin saturation.
3. Classify as secondary (low/low-normal LH) versus primary (high LH).
4. Screen for functional causes: BMI, opioid use, sleep apnea, alcohol.
5. If prolactin >25 ng/mL or LH <1 IU/L, order pituitary MRI.
6. Address reversible causes for a minimum of 3 months before starting pharmacotherapy.
7. If fertility desired: start enclomiphene 12.5 mg/day or hCG 1,500 to 2,000 IU three times per week.
8. If fertility complete and TRT initiated: monitor hematocrit, PSA (men over 40), and testosterone at 3 and 6 months.

Monitoring and Long-Term Follow-Up

Targets on Therapy

The Endocrine Society targets a mid-normal testosterone range of 400 to 700 ng/dL on therapy. [1] Free testosterone (calculated from total testosterone and SHBG) provides a more accurate picture in men with high SHBG from liver disease, thyroid dysfunction, or older age.

Men on enclomiphene should have testosterone, LH, and estradiol checked every 3 months. Estradiol above 50 pg/mL on enclomiphene may require low-dose aromatase inhibitor (anastrozole 0.5 mg twice weekly) to control estrogen-related side effects (gynecomastia, fluid retention).

Bone Density

Secondary hypogonadism of any duration longer than 12 months is associated with reduced bone mineral density. [18] Dual-energy X-ray absorptiometry (DEXA) scanning is recommended at baseline and every 1 to 2 years during treatment to confirm stabilization or improvement. Vertebral fracture risk increases 2.3-fold in men with testosterone below 200 ng/dL for more than 2 years. [18]

Semen Analysis on Fertility-Preserving Therapy

Men receiving enclomiphene or hCG with fertility goals should have a semen analysis at 3 and 6 months. If sperm concentration remains below 5 million/mL at 6 months on hCG monotherapy, adding recombinant FSH 75 IU three times weekly is standard practice at most male fertility centers. [14]